Format

Send to

Choose Destination
Thorax. 2016 Jan;71(1):88-90. doi: 10.1136/thoraxjnl-2015-207983.

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary.

Author information

1
Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK Cambridge Centre for Lung Infection, Papworth Hospital, Cambridge, UK.
2
Cardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland, USA.
3
Department of Pediatrics, Columbia University Medical Center, Pediatric Infectious Diseases, New York, New York, USA.
4
Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, Colorado, USA.
5
INSERM U1173, UFR Simone Veil, Versailles-Saint-Quentin University, Saint-Quentin en Yvelines, France AP-HP, Service de Microbiologie, Hôpital Raymond Poincaré, Garches, France.
6
Department of Medicine, National Jewish Health, Denver, Colorado, USA.
7
Division of Pulmonary and Critical Care Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
8
Department of Respiratory Medicine, Royal Brompton Hospital, London, UK.
9
Department of Respiratory Medicine, Freeman Hospital High Heaton, Newcastle, UK.
10
Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA.
11
The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA.
12
Department of Pediatrics, Sahlgrenska University Hospital, Gothenburg, Sweden.
13
Service de Pneumo-Pédiatrie, Université René Descartes, Hôpital Necker-Enfants Malades, Paris, France.
14
Division of Child Health, Obstetrics & Gynaecology, University of Nottingham, Nottingham, UK.
15
Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands.
16
Department. of Microbiology, University of Texas Health Science Center, Tyler, Texas, USA.
17
Divisions of Infectious Diseases, Public Health and Preventive Medicine, Oregon Health and Science University, Portland, Oregon, USA.
18
Cystic Fibrosis Foundation, Bethesda, Maryland, USA.
19
Cambridge Centre for Lung Infection, Papworth Hospital, Cambridge, UK.

Abstract

Non-tuberculous mycobacteria (NTM) are ubiquitous environmental organisms that can cause chronic pulmonary infection, particularly in individuals with pre-existing inflammatory lung disease, such as cystic fibrosis (CF). Pulmonary disease (PD) caused by NTM has emerged as a major threat to the health of individuals with CF, but remains difficult to diagnose and problematic to treat. In response to this challenge, the US Cystic Fibrosis Foundation (CFF) and the European Cystic Fibrosis Society (ECFS) convened a panel of 19 experts to develop consensus recommendations for the screening, investigation, diagnosis and management of NTM-PD in individuals with CF. PICO (population, intervention, comparison, outcome) methodology and systematic literature reviews were employed to inform draft recommendations, which were then modified to achieve consensus and subsequently circulated for public consultation within the USA and European CF communities. We have thus generated a series of pragmatic, evidence-based recommendations as an initial step in optimising management for this challenging condition.

KEYWORDS:

Atypical Mycobacterial Infection; Cystic Fibrosis; Respiratory Infection

PMID:
26678435
PMCID:
PMC4717423
DOI:
10.1136/thoraxjnl-2015-207983
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center